Lexicon Pharmaceuticals (LXRX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Lexicon Pharmaceuticals

NasdaqCM•Healthcare•Biotechnology

$2.24-0.02(-0.01%)Market closed

Market Cap

$892.81M

P/S

21.5x

P/B

5.1x

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

How this company scores

AverageMetricSide Score: 50/100

Strongest: Balance Sheet & Red Flags (20/25); weakest: Growth (9/25).

Profitability10/25

Growth9/25

Balance Sheet & Red Flags20/25

Cash & Earnings Quality11/25

Strengths

Low leverageCash-backed earningsProfit converts from growthImproving leverage

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 21.5x5y range 5.3x – 30108.5x

Currently below its 19-quarter median.

P/B · 5.1x5y range 1.4x – 5.3x

Currently above its 19-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $892.81M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $41.47M
Q. Revenue: $692,000
TTM EBITDA: $-53.70M
TTM Op. Income: $-54.50M
Q. Op. Income: $-26.54M
TTM Net Income: $-61.12M
Q. Net Income: $-31.77M
EPS: $-0.07
Shares Out.: $437.65M

$41.47M in TTM revenue declined 29.0% YoY, reaching $692,000 last quarter. TTM EBITDA of $-53.70M and TTM operating income of $-54.50M show growth is flowing through to the bottom line. However, net income is negative at $61.12M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 29% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 94.4%
EBITDA Margin: -3820.5%
Op. Margin: -3835.3%
Net Margin: -4591.8%

Op. margin of -3835.3% is down 3848.2% YoY — costs are rising relative to revenue. Net margin at -4591.8% and gross margin of 94.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 29733% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 21.5x
P/B Ratio: 5.1x

P/S of 21.5x and P/B of 5.1x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $250.06M
Cash: $40.92M
Long-Term Debt: $51.44M
Book Value: $174.53M
D/E Ratio: 0.3
Debt/EBITDA: N/A

With $250.06M in assets and $51.44M in long-term debt, D/E is 0.3and book value is $174.53M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 32% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-9.19M
TTM Free Cash Flow: $-64.99M
FCF Margin: -156.7%
FCF / Net Income: 1.1

TTM FCF of $-64.99M on $-9.19M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 37% — a weakening trend.